• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Celldex Reports First Quarter 2025 Financial Results and Provides Corporate Update

    5/8/25 4:01:00 PM ET
    $CLDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $CLDX alert in real time by email
    • Strong execution and progress across pipeline with multiple key data read outs expected in 2025
    • Late breaking oral presentation on Phase 2 CSU program at EAACI 2025 in June
    • Phase 3 barzolvolimab CSU studies enrollment ongoing; Phase 3 program in CIndU under development
    • Phase 2 EOE study enrollment complete; ongoing enrollment in Phase 2 PN and AD studies
    • Celldex's first bispecific for inflammatory diseases, CDX-622, Phase 1 study ongoing

    HAMPTON, N.J., May 08, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the first quarter ended March 31, 2025 and provided a corporate update.

    "In the first quarter of 2025, we presented data from our Phase 2 studies in chronic spontaneous and chronic inducible urticaria that demonstrated that barzolvolimab greatly improved quality of life for patients," said Anthony Marucci, Co-founder, President and Chief Executive Officer of Celldex Therapeutics. "Barzolvolimab has consistently demonstrated best-in-class efficacy in chronic urticaria, with very high rates of complete response, and it's especially meaningful to see these results translate into improved quality of life for patients living with a severe disease that impacts nearly every aspect of their daily lives."

    "We expect 2025 will be a year of continued execution across our robust pipeline supported by important data from our barzolvolimab Phase 2 studies in CSU, CIndU and EOE and our CDX-622 Phase 1 study in healthy volunteers. Next month, 76 week data from the Phase 2 CSU study will be presented in a late breaking oral session at EAACI where we will discuss barzolvolimab's potential to achieve sustained disease control after treatment withdrawal. We think this data will be important to the field and to patients who need treatment options that offer rapid, profound and durable control of their disease. To this end, we continue to work to bring this important medicine to patients."

    Recent Program Highlights

    Barzolvolimab - KIT Inhibitor Program

    Barzolvolimab is a humanized monoclonal antibody developed by Celldex that binds the KIT receptor with high specificity and potently inhibits its activity. The KIT receptor tyrosine kinase is expressed in a variety of cells, including mast cells, which mediate inflammatory responses such as hypersensitivity and allergic reactions. KIT signaling controls the differentiation, tissue recruitment, survival and activity of mast cells. 

    Chronic Urticarias

    Phase 3 Development

    • A global Phase 3 program in chronic spontaneous urticaria (CSU) consisting of two Phase 3 trials (EMBARQ-CSU1 and EMBARQ-CSU2) was initiated in July and enrollment is ongoing. The studies are designed to establish the efficacy and safety of barzolvolimab in adult patients with CSU who remain symptomatic despite H1 antihistamine treatment and also include patients who remain symptomatic after treatment with biologics. EMBARQ-CSU1 and EMBARQ-CSU2 will enroll approximately 915 patients each across approximately 40 countries and 500 sites.

    • The Company is currently planning a global Phase 3 program in chronic inducible urticaria (CIndU), which is expected to initiate in 2025.

    Phase 2 Development

    • Barzolvolimab met all primary and secondary endpoints at 12 weeks across the Company's Phase 2 studies in CSU and CIndU. Results were highly statistically significant and clinically meaningful.



      • 76 week data, which includes 24-weeks of off-treatment follow-up, from the Phase 2 study in CSU have been accepted for a late breaking oral presentation on Friday, June 13th at 9:12 am BST/10:12 am CEST/4:12 am ET at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 being held in Glasgow, Scotland. The Company will host a webcast on Thursday, June 12th at 6:00 pm ET to present the data.

      • 20 week treatment data from the Phase 2 CIndU study will be presented later this year. After completing treatment, patients on study are followed for 24 weeks and patients with returning symptoms can enter an open label extension during the follow up period.

      • 52 week quality of life data from the Phase 2 CSU study were presented in March at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 2025. Rapid and sustained improvement in urticaria control (UCT) and quality of life (DLQI) were observed in patients with CSU refractory to antihistamines. Up to 82% of patients reported that CSU symptoms no longer had an impact on their quality of life at Week 52 and up to 95% of patients reported meaningful improvement in quality of life based on DLQI at Week 52. Up to 82% of patients reported well-controlled urticaria based on UCT and approximately half of patients reported complete control at Week 52.

      • 12 week quality of life data from the Phase 2 CIndU study were presented in March at the AAAAI Annual Meeting 2025. A marked and rapid improvement in UCT and DLQI was observed and sustained through the 12-week period in patients with ColdU and SD. Up to 60% of patients reported that CIndU symptoms no longer had an impact on their quality of life at Week 12 and up to 69% of patients reported well-controlled urticaria based on UCT at Week 12.

    Additional Indications

    • Enrollment is complete in the Phase 2 study in eosinophilic esophagitis (EoE) and data from this study is expected in 2025. This randomized, double-blind, placebo-controlled, parallel group study is evaluating the efficacy and safety profile of barzolvolimab in patients with active EoE.

    • Enrollment continues in the Phase 2 study in prurigo nodularis (PN). This randomized, double-blind, placebo-controlled, parallel group study is evaluating the efficacy and safety profile of barzolvolimab in approximately 120 patients with moderate to severe PN.

    • Enrollment is ongoing in the Phase 2 study in atopic dermatitis (AD). This randomized, double-blind, placebo-controlled, parallel group study is evaluating the efficacy and safety profile of barzolvolimab in approximately 120 patients with moderate to severe AD.

    Bispecific Antibody Platform

    CDX-622 – Bispecific SCF & TSLP

    CDX-622 targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin (TSLP) and depleting mast cells via stem cell factor (SCF) starvation. Combined neutralization of SCF and TSLP with CDX-622 is expected to simultaneously reduce tissue mast cells and inhibit Type 2 inflammatory responses to potentially offer enhanced therapeutic benefit in inflammatory and fibrotic disorders.

    • Enrollment is ongoing in the Phase 1 study in healthy volunteers. This two-part randomized, double-blind, placebo-controlled, dose escalation study is designed to assess the safety, pharmacokinetics, and pharmacodynamics of single ascending doses (Part 1) and multiple ascending doses (Part 2) of CDX-622 in up to 56 healthy participants. The pharmacodynamic biomarkers from blood and skin will be highly informative on the ability of CDX-622 to engage and neutralize SCF and TSLP. Data from Part 1 of the study is expected in 2025.

    First Quarter 2025 Financial Highlights and 2025 Guidance

    Cash Position: Cash, cash equivalents and marketable securities as of March 31, 2025 were $673.3 million compared to $725.3 million as of December 31, 2024. The decrease was primarily driven by first quarter cash used in operating activities of $54.4 million. At March 31, 2025, Celldex had 66.4 million shares outstanding.

    Revenues: Total revenue was $0.7 million in the first quarter of 2025, compared to $0.2 million for the comparable period in 2024. The increase in revenue was primarily due to an increase in services performed under our manufacturing and research and development agreements with Rockefeller University.

    R&D Expenses: Research and development (R&D) expenses were $52.6 million in the first quarter of 2025, compared to $31.7 million for the comparable period in 2024. The increase in R&D expenses was primarily due to an increase in barzolvolimab clinical trial, barzolvolimab contract manufacturing and personnel expenses.

    G&A Expenses: General and administrative (G&A) expenses were $10.8 million in the first quarter of 2025, compared to $9.1 million for the comparable period in 2024. The increase in G&A expenses was primarily due to an increase in stock-based compensation expense.

    Net Loss: Net loss was $53.8 million, or ($0.81) per share, for the first quarter of 2025, compared to a net loss of $32.8 million, or ($0.56) per share, for the comparable period in 2024.

    Financial Guidance: Celldex believes that the cash, cash equivalents and marketable securities at March 31, 2025 are sufficient to meet estimated working capital requirements and fund current planned operations through 2027.

    About Celldex Therapeutics, Inc.

    Celldex is a clinical stage biotechnology company leading the science at the intersection of mast cell biology and the development of transformative therapeutics for patients. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Visit www.celldex.com.

    Forward Looking Statement

    This release contains "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to successfully complete research and further development and commercialization of Company drug candidates, including barzolvolimab (also referred to as CDX-0159), in current or future indications; the uncertainties inherent in clinical testing and accruing patients for clinical trials; our limited experience in bringing programs through Phase 3 clinical trials; our ability to manage and successfully complete multiple clinical trials and the research and development efforts for our multiple products at varying stages of development; the availability, cost, delivery and quality of clinical materials produced by our own manufacturing facility or supplied by contract manufacturers, who may be our sole source of supply; the timing, cost and uncertainty of obtaining regulatory approvals; the failure of the market for the Company's programs to continue to develop; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; our ability to continue to obtain capital to meet our long-term liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials that we have initiated or plan to initiate; and other factors listed under "Risk Factors" in our annual report on Form 10-K and quarterly reports on Form 10-Q.

    All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.

    Company Contact

    Sarah Cavanaugh

    Senior Vice President, Corporate Affairs & Administration

    (508) 864-8337

    [email protected]

    Patrick Till

    Meru Advisors

    (484) 788-8560

    [email protected]







    CELLDEX THERAPEUTICS, INC.
    (In thousands, except per share amounts)
          
       Three Months
    Consolidated Statements of Operations Data Ended March 31,
        2025   2024 
       (Unaudited)
    Revenues:    
    Product development and licensing agreements $50  $2 
    Contracts and grants  645   154 
          
    Total revenues  695   156 
          
    Operating expenses:    
    Research and development  52,614   31,661 
    General and administrative  10,820   9,103 
          
    Total operating expenses  63,434   40,764 
          
    Operating loss  (62,739)  (40,608)
          
    Investment and other income, net  8,943   7,800 
          
    Net loss $(53,796) $(32,808)
          
    Basic and diluted net loss per common share $(0.81) $(0.56)
          
    Shares used in calculating basic and diluted net loss per share  66,383   58,871 
          
          
          
          
    Condensed Consolidated Balance Sheet Data March 31 December 31
        2025   2024 
       (Unaudited)  
    Assets    
    Cash, cash equivalents and marketable securities $673,291  $725,281 
    Other current assets  20,466   21,878 
    Property and equipment, net  4,601   4,346 
    Intangible and other assets, net  41,113   40,835 
     Total assets $739,471  $792,340 
          
    Liabilities and stockholders' equity    
    Current liabilities $32,018  $39,501 
    Long-term liabilities  4,472   5,834 
    Stockholders' equity  702,981   747,005 
     Total liabilities and stockholders' equity $739,471  $792,340 
          







    Primary Logo

    Get the next $CLDX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CLDX

    DatePrice TargetRatingAnalyst
    4/28/2025$64.00Buy
    Canaccord Genuity
    3/20/2025$46.00Overweight
    Morgan Stanley
    2/13/2025$44.00Buy
    UBS
    10/7/2024$70.00Buy
    Citigroup
    9/30/2024$45.00Neutral
    Goldman
    9/27/2024Outperform → Peer Perform
    Wolfe Research
    6/18/2024$58.00Buy
    Stifel
    6/11/2024$51.00Outperform
    Wolfe Research
    More analyst ratings

    $CLDX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Celldex Reports First Quarter 2025 Financial Results and Provides Corporate Update

      Strong execution and progress across pipeline with multiple key data read outs expected in 2025Late breaking oral presentation on Phase 2 CSU program at EAACI 2025 in JunePhase 3 barzolvolimab CSU studies enrollment ongoing; Phase 3 program in CIndU under developmentPhase 2 EOE study enrollment complete; ongoing enrollment in Phase 2 PN and AD studiesCelldex's first bispecific for inflammatory diseases, CDX-622, Phase 1 study ongoing HAMPTON, N.J., May 08, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the first quarter ended March 31, 2025 and provided a corporate update. "In the first quarter of 2025, we presented data from our Ph

      5/8/25 4:01:00 PM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult to Treat Disease

      HAMPTON, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Celldex announced today the presentation of histology data from the Company's ongoing Phase 2 study of barzolvolimab in eosinophilic esophagitis (EoE). Biopsies taken during screening demonstrate the presence of high numbers of intraepithelial mast cells in participants with active EoE and correlate with eosinophil counts, supporting the hypothesis that treating EoE with barzolvolimab—a mast cell depleting agent—could provide promising therapeutic benefit. The data were discussed in a poster presentation at the Digestive Disease Week (DDW) 2025 conference in San Diego today. Celldex announced in February 2025 that enrollment to the Phase 2 st

      5/5/25 4:01:00 PM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Celldex Therapeutics to Present at Upcoming Investor Conferences

      HAMPTON, N.J., March 04, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in fireside chats at two upcoming conferences: TD Cowen 45th Annual Health Care Conference on Tuesday, March 4th at 1:50 p.m. ET Leerink Partners Global Healthcare Conference on Tuesday, March 11th at 1:00 p.m. ET Live webcasts of the presentations will be available on the "Events & Presentations" page of the "Investors & Media" section of the Celldex website. Replays will be available for 90 days following the event. About Celldex Therapeutics, Inc.Celldex is a clinical stage biotechnology company leading the science at the intersection of mast ce

      3/4/25 8:01:00 AM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $CLDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Celldex Therapeutics Inc.

      SC 13G/A - Celldex Therapeutics, Inc. (0000744218) (Subject)

      11/14/24 7:47:25 PM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Celldex Therapeutics Inc.

      SC 13G/A - Celldex Therapeutics, Inc. (0000744218) (Subject)

      11/14/24 12:18:08 PM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Celldex Therapeutics Inc.

      SC 13G/A - Celldex Therapeutics, Inc. (0000744218) (Subject)

      11/14/24 6:12:56 AM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $CLDX
    Leadership Updates

    Live Leadership Updates

    See more
    • Celldex Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors

      HAMPTON, N.J., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that it has appointed Rita Jain, M.D. to the Company's Board of Directors. "We are pleased to welcome Dr. Jain to the Celldex Board of Directors at this important time in the Company's trajectory," said Anthony Marucci, Co-founder, President and Chief Executive Officer of Celldex Therapeutics. "Dr. Jain's deep background in drug development strongly complements our Board's skills and experiences, and we look forward to her contributions as we continue to advance our programs into later stage development." Dr. Jain added, "I am excited to join Celldex, whose emerging data suggests tha

      2/16/23 4:01:00 PM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Biosion, Inc. Appoints Joel Edwards, MBA, as Chief Business Officer

      NEWARK, Del. and NANJING, China, Feb. 21, 2022 /PRNewswire/ -- Biosion, Inc. ("Biosion"), a global clinical stage biotechnology company, today announced the appointment of Joel Edwards as chief business officer. In this position, he is responsible for strategic leadership over all aspects of the company's global business development and alliance management activities. He will report to Dr. Mingjiu Chen, chief executive officer (CEO). Prior to joining Biosion, Mr. Edwards was most recently vice president of corporate strategy and operations at Ionis Pharmaceuticals. "We are delighted to welcome Joel to our executive leadership team in this important role as we continue to expand global busin

      2/21/22 12:00:00 AM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Biosion, Inc. Appoints Anthony Yeh, Ph.D., as Chief Strategy Officer and Head of China BD

      NEWARK, Del. and NANJING, China, Jan. 3, 2022 /PRNewswire/ -- Biosion, Inc. ("Biosion"), a global clinical stage biotechnology company, today announced the appointment of Dr. Anthony Yeh to the position of Chief Strategy Officer and Head of China business development (BD), where he will lead corporate strategy, China BD, and capital fundraising. He will report to Dr. Mingjiu Chen, Chief Executive Officer (CEO). Prior to joining Biosion, Dr. Yeh was most recently Vice President, Head of Corporate Strategy, Investor Relations and Capital Market at CStone Pharmaceuticals (HKSE:2616). "We are pleased to welcome Anthony to Biosion as we continue to expand globally and strengthen our executive le

      1/3/22 5:00:00 AM ET
      $ABT
      $CLDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: In Vitro & In Vivo Diagnostic Substances

    $CLDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Canaccord Genuity initiated coverage on Celldex Therapeutics with a new price target

      Canaccord Genuity initiated coverage of Celldex Therapeutics with a rating of Buy and set a new price target of $64.00

      4/28/25 8:36:51 AM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Morgan Stanley initiated coverage on Celldex Therapeutics with a new price target

      Morgan Stanley initiated coverage of Celldex Therapeutics with a rating of Overweight and set a new price target of $46.00

      3/20/25 7:59:39 AM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • UBS initiated coverage on Celldex Therapeutics with a new price target

      UBS initiated coverage of Celldex Therapeutics with a rating of Buy and set a new price target of $44.00

      2/13/25 8:07:26 AM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $CLDX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • PRESIDENT & CEO Marucci Anthony S bought $308,430 worth of shares (11,500 units at $26.82), increasing direct ownership by 40% to 40,284 units (SEC Form 4)

      4 - Celldex Therapeutics, Inc. (0000744218) (Issuer)

      11/12/24 8:01:10 AM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $CLDX
    SEC Filings

    See more
    • SEC Form 10-Q filed by Celldex Therapeutics Inc.

      10-Q - Celldex Therapeutics, Inc. (0000744218) (Filer)

      5/8/25 4:06:23 PM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Celldex Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Celldex Therapeutics, Inc. (0000744218) (Filer)

      5/8/25 4:01:36 PM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form DEF 14A filed by Celldex Therapeutics Inc.

      DEF 14A - Celldex Therapeutics, Inc. (0000744218) (Filer)

      4/21/25 8:01:28 AM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $CLDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Marino James J gifted 10,500 shares, decreasing direct ownership by 83% to 2,204 units (SEC Form 4)

      4 - Celldex Therapeutics, Inc. (0000744218) (Issuer)

      11/20/24 4:02:46 PM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • PRESIDENT & CEO Marucci Anthony S bought $308,430 worth of shares (11,500 units at $26.82), increasing direct ownership by 40% to 40,284 units (SEC Form 4)

      4 - Celldex Therapeutics, Inc. (0000744218) (Issuer)

      11/12/24 8:01:10 AM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SVP AND CFO Martin Samuel Bates exercised 20,169 shares at a strike of $10.16 and sold $608,315 worth of shares (17,172 units at $35.42), increasing direct ownership by 12% to 28,125 units (SEC Form 4)

      4 - Celldex Therapeutics, Inc. (0000744218) (Issuer)

      6/18/24 4:05:20 PM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $CLDX
    Financials

    Live finance-specific insights

    See more
    • Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria

      First to demonstrate clinical benefit in patients with chronic inducible urticaria (CIndU) in large, randomized, placebo-controlled study Favorable safety and tolerability Plan to advance CIndU into Phase 3 developmentCompany to host webcast call Monday at 8:00 am ET HAMPTON, N.J., Oct. 26, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today positive results from the Company's Phase 2 clinical trial of barzolvolimab in two of the most common forms of chronic inducible urticaria (CIndU)—cold urticaria (ColdU) and symptomatic dermographism (SD). The study includes patients who remain symptomatic despite treatment with antihistamines. Barzolvolimab is a humaniz

      10/26/24 5:43:20 PM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024

      - 71% of patients (150 mg Q4W) achieved complete response at Week 52 -- Rapid, profound and durable improvement in UAS7 as early as Week 1 with a deepening of response over 52 weeks -- Robust improvement across omalizumab-experienced/refractory/naïve disease -- Well tolerated through 52 weeks -- Enrollment to Global Phase 3 CSU trials underway -- Company to host webcast today at 12:00 pm ET/6:00 pm CEST - HAMPTON, N.J., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today new data demonstrating sustained and deepening disease efficacy and a well tolerated safety profile over a 52 week treatment period for barzolvolimab in chronic spontaneous

      9/25/24 10:45:00 AM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria

      - Primary and secondary endpoints met with clinically meaningful and statistically significant decreases in urticaria disease activity across multiple dose groups -- Sustained activity with rapid onset within 2 weeks -- Similar improvement in omalizumab-experienced/refractory and omalizumab-naïve disease consistent with unique mechanism of action -- Favorable safety profile -- 52 week results and Phase 3 CSU trial initiations anticipated in 2024 -- Company to host webcast February 25th at 9:45 am ET- HAMPTON, N.J., Feb. 24, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today positive 12 week results from the Company's Phase 2 clinical trial of barzolvolim

      2/24/24 2:05:00 PM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care